Literature DB >> 28116842

Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients.

R Núñez-Torres1, J Macías1,2, A Rivero-Juarez3,4, K Neukam1,2, D Merino5, F Téllez6, N Merchante1,2, J Gómez-Mateos1,2, A Rivero3, J A Pineda1, L M Real1,2.   

Abstract

OBJECTIVES: Fatty liver disease (FLD) is frequently observed in HIV-infected patients. Obesity and type 2 diabetes mellitus (T2DM) are strongly associated with FLD. Because genetic variants within the fat mass and obesity-associated (FTO) gene have been associated with both pathologies, our aim was to evaluate the association of single nucleotide polymorphisms (SNPs) within the FTO, previously related to obesity or T2DM, with FLD in HIV-infected patients.
METHODS: FLD was defined as a value of the controlled attenuation parameter (CAP) ≥ 238 dB/m, obtained by transient elastography. Four SNPs within FTO intron 1 (rs11642841, rs8050136, rs9939609 and rs9940128) were genotyped in 421 individuals using a custom Golden Gate protocol. The results were replicated in a validation sample consisting of a further 206 HIV-infected patients. Multivariate logistic regression analyses were conducted in the entire population.
RESULTS: Three SNPs (rs8050136, rs9939609 and rs9940128) were associated with FLD, with rs9940128 showing the strongest association. This polymorphism also showed an association with FLD in the validation sample. In total, rs9940128 was genotyped in 627 HIV-infected patients, including 267 (42.6%) FLD-diagnosed individuals. The frequency of FLD among rs9940128 AA carriers was 55.7% (63 of 113 individuals) and that in patients without this genotype was 39.7% (204 of 514 individuals) [P = 0.009; adjusted odds ratio 1.88; 95% confidence interval (CI) 1.17-3.01].
CONCLUSIONS: Variations within FTO may be predictors of FLD in HIV-infected patients independently of metabolic factors.
© 2017 British HIV Association.

Entities:  

Keywords:  HIV; fat mass and obesity-associated gene; fatty liver disease; genetics; polymorphisms

Mesh:

Substances:

Year:  2017        PMID: 28116842     DOI: 10.1111/hiv.12489

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  4 in total

Review 1.  Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies.

Authors:  N Merchante; M Rodríguez-Fernández; J A Pineda
Journal:  Curr HIV/AIDS Rep       Date:  2020-02       Impact factor: 5.071

2.  Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy.

Authors:  Catalina Barceló; Monia Guidi; Christian W Thorball; Christian Hammer; Aziz Chaouch; Alexandra U Scherrer; Barbara Hasse; Matthias Cavassini; Hansjakob Furrer; Alexandra Calmy; Sebastian Haubitz; Enos Bernasconi; Thierry Buclin; Jacques Fellay; Philip E Tarr; Chantal Csajka
Journal:  Open Forum Infect Dis       Date:  2020-01-22       Impact factor: 4.423

3.  Relationship of FTO gene variations with NAFLD risk in Chinese men.

Authors:  Xuefen Chen; Yong Gao; Xiaobo Yang; Haiying Zhang; Zengnan Mo; Aihua Tan
Journal:  Open Life Sci       Date:  2020-11-30       Impact factor: 0.938

4.  FTO Polymorphisms are Associated with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Susceptibility in the Older Chinese Han Population.

Authors:  Zhan Gu; Yan Bi; Fan Yuan; Ruirui Wang; Dong Li; Jianying Wang; Xiaojuan Hu; Guang He; Lei Zhang; Bao-Cheng Liu
Journal:  Clin Interv Aging       Date:  2020-08-11       Impact factor: 4.458

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.